Prnewswire·2025-12-24 06:23Core Viewpoint - Sanofi has announced an agreement to acquire Dynavax Technologies Corporation for $15.50 per share, representing a 39% premium over Dynavax's closing share price on December 23, 2025, enhancing Sanofi's adult immunization portfolio with Dynavax's vaccines [1][4]. Group 1: Acquisition Details - The acquisition includes Dynavax's marketed adult hepatitis B vaccine HEPLISAV-B and a shingles vaccine candidate Z-1018, which is in phase 1/2 clinical development [2]. - The total equity value of the acquisition is approximately $2.2 billion, with the offer price reflecting a 46% premium over the 3-month volume-weighted average price of Dynavax as of December 23, 2025 [4]. - The transaction has been unanimously approved by Dynavax's board of directors and is expected to close in the first quarter of 2026, subject to customary closing conditions [5][7]. Group 2: Product Information - HEPLISAV-B is a two-dose adult hepatitis B vaccine that provides high levels of seroprotection faster than traditional three-dose vaccines [2][8]. - The shingles vaccine candidate Z-1018 aims to address significant public health needs, as shingles affects one in three adults over their lifetime [3]. Group 3: Market Opportunity - There is a significant unmet health need for hepatitis B and shingles vaccination, particularly among nearly 100 million unvaccinated adults in the US born before 1991 [3]. - Chronic hepatitis B infection can lead to severe liver damage, while shingles can cause long-term nerve pain and other serious complications [3].